EKSO vs LGVN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EKSO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
LGVN exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from extreme operating losses (-1479.18% margin) and negative revenue growth (-39.50% YoY), suggesting a failing business model or a high-risk clinical stage. While the current ratio of 1.33 provides a temporary liquidity cushion and analyst targets are aggressively optimistic, the deterministic data points to a high probability of further capital erosion.
Compare Another Pair
Related Comparisons
EKSO vs LGVN: Head-to-Head Comparison
This page compares Ekso Bionics Holdings, Inc. (EKSO) and Longeveron Inc. (LGVN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.